About Lantern Pharma Inc.
https://www.lanternpharma.comLantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer.
CEO
Panna Sharma
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 17
Ratings Snapshot
Rating : C+
Price Target
Institutional Ownership
BIOS CAPITAL MANAGEMENT, LP
Shares:1.02M
Value:$3.6M
VANGUARD GROUP INC
Shares:384.04K
Value:$1.36M
CM MANAGEMENT, LLC
Shares:225K
Value:$796.5K
Summary
Showing Top 3 of 34
About Lantern Pharma Inc.
https://www.lanternpharma.comLantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $4.35M ▼ | $-4.18M ▲ | 0% | $-0.39 ▲ | $-4.17M ▲ |
| Q2-2025 | $0 | $4.65M ▼ | $-4.33M ▲ | 0% | $-0.4 ▲ | $-4.65M ▲ |
| Q1-2025 | $0 | $4.77M ▼ | $-4.54M ▲ | 0% | $-0.42 ▲ | $-4.77M ▲ |
| Q4-2024 | $0 | $5.85M ▲ | $-5.88M ▼ | 0% | $-0.54 ▼ | $-5.82M ▼ |
| Q3-2024 | $0 | $5.18M | $-4.51M | 0% | $-0.42 | $-5.18M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $12.36M ▼ | $13.63M ▼ | $4.04M ▼ | $9.59M ▼ |
| Q2-2025 | $15.9M ▼ | $17.42M ▼ | $4.9M ▲ | $12.52M ▼ |
| Q1-2025 | $19.72M ▼ | $21.1M ▼ | $4.32M ▼ | $16.78M ▼ |
| Q4-2024 | $24.01M ▼ | $25.57M ▼ | $4.38M ▲ | $21.19M ▼ |
| Q3-2024 | $28.05M | $30.29M | $3.7M | $26.6M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-4.18M ▲ | $-4.57M ▼ | $5.93M ▲ | $971.78K ▲ | $2.33M ▲ | $-4.57M ▼ |
| Q2-2025 | $-4.33M ▲ | $-3.94M ▲ | $3.59M ▲ | $0 | $-316.19K ▲ | $-3.94M ▲ |
| Q1-2025 | $-4.54M ▲ | $-4.38M ▼ | $3.24M ▼ | $0 | $-1.13M ▼ | $-4.38M ▼ |
| Q4-2024 | $-5.88M ▼ | $-3.97M ▲ | $3.45M ▲ | $0 ▼ | $-591.74K ▲ | $-3.97M ▲ |
| Q3-2024 | $-4.51M | $-5.58M | $680.35K | $11.99K | $-4.87M | $-5.59M |
CEO
Panna Sharma
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 17
Ratings Snapshot
Rating : C+
Price Target
Institutional Ownership
BIOS CAPITAL MANAGEMENT, LP
Shares:1.02M
Value:$3.6M
VANGUARD GROUP INC
Shares:384.04K
Value:$1.36M
CM MANAGEMENT, LLC
Shares:225K
Value:$796.5K
Summary
Showing Top 3 of 34